Message From Our Chief

Message From Our Chief

Here in the Division of Pulmonary, Critical Care and Sleep Medicine at Mount Sinai, the last few years have been extraordinary. In 2015 we opened the Mount Sinai-National Jewish Health Respiratory Institute, www.therespiratoryinstitute.org and created a model for delivering patient centered, interdisciplinary, state-of-the-art care for patients with simple and complex respiratory diseases, which also includes physicians from Gastroenterology, Cardiology, Otolaryngology, and Rheumatology.  Of particular note for you, for out-of-town referrals, we provide comprehensive multi-day visits for the evaluation and treatment of undiagnosed respiratory diseases. In 2017, five of our Respiratory Institute physicians at Mount Sinai Hospital were recognized in New York Magazine’s Best Pulmonary Doctors list; this is the highest number of listed pulmonary physicians from any program in New York.  To further increase access to our Respiratory Institute, in 2018 we will open up a new location at the Mount Sinai Downtown location at Union Square.  This location will be directed by Dr. David Steiger and will include all of the features that have led to success at the Mount Sinai Hospital Respiratory Institute that is directed by Dr. Louis DePalo.

We also have the largest sarcoidosis program in the northeast and a long tradition of sarcoidosis research and treatment. Adam Morgenthau, MD, directs the Sarcoidosis Clinic at Mount Sinai, which sees approximately 100 patients with sarcoidosis a month and has tremendous experience in diagnosis and management of sarcoidosis given such an extensive patient base. Linda Rogers, MD is the Director of the Respiratory Institute asthma program that has developed novel clinical pathways for the diagnosis and treatment of patients with simple and complex asthma.  She is the principal investigator for the Mount Sinai site in the American Lung Association Airways Clinical Research Centers (ACRC) Network that provides access to important clinical trials.

Our Lung Cancer Research Program has identified key molecular pathways that are activated in the progression of adenocarcinoma from indolent tumor to metastatic tumor and this has become increasingly important as efforts to detect early stage lung cancers begins to pay off.  Our pioneering screening program run by Claudia Henschke, MD, PhD, Professor of Radiology, has shown that CT scans can find 85 percent of lung cancers in their earliest, most treatable, stages and with greater accuracy. This screening program has now been implemented throughout the Mount Sinai Health System and internationally as the IELCAP consortium.

At the Respiratory Institute, we are one of only two sites in the city for National Institutes of Health (NIH) multi-center critical care trials (PETAL) for acute lung injury. We hope that these studies and the close collaborative relationship with Emergency Medicine team within the trials will identify new opportunities for the prevention and treatment of adult respiratory distress syndrome.

Our faculty have been very productive in advancing respiratory disease science and in transmitting information to peers, students and patients. Our faculty have published over 75 papers in 2016-17, presented in major symposia at ATS, ACCP, international symposia such as the Chinese International Society for Respiratory Disease and the International Association for the Study of Lung Cancer.

This is just the tip of the iceberg of what’s being done at the Respiratory Institute.

Sincerely,

Charles A. Powell, MD

Janice and Coleman Rabin Professor of Medicine
Chief, Catherine and Henry J. Gaisman Division of Pulmonary, Critical Care, and Sleep Medicine
CEO, Mount Sinai-National Jewish Respiratory Institute
@CAP_MSNJHRI